China's first specific anti-COVID-19 drug will soon come out, and it will take effect immediately after infusion. What is its principle?

With the development of the epidemic situation in COVID-19, the vaccination rate is uneven when the prevention and control measures abroad are not implemented in place. Now, five COVID-19 mutant strains have been listed as? Care about mutants? (variable of concern, VOC), which is currently classified by the World Health Organization as Delta (B. 1.6 17.2), Alpha (B.1.7) and Beta (B.1.35/). Care about mutants? . At present, the epidemic situation in COVID-19 has seriously affected human society, so it is urgent to control the epidemic situation.

This situation also means that we must, as always, strictly abide by epidemic prevention regulations and do a good job in personal protection. Although everyone was affected by the COVID-19 epidemic, they still didn't lose heart. There's also good news recently. The team of Professor Zhang from Tsinghua University Medical College announced that the first anti-specific drug combination therapy of Ambavimab and Romisimab in China has been launched. This special drug through intravenous drip has been approved by the relevant departments.

This special anti-COVID-19 drug takes effect immediately after being injected into the body through intravenous drip. The principle is very simple, that is, screening out two kinds of antibodies with strong blocking ability against COVID-19, and let them fight against COVID-19 together. This drug therapy can reduce the hospitalization rate and mortality rate of high-risk outpatients in COVID-19. After the introduction of this special anti-COVID-19 drug, it quickly attracted public attention.

Since the ravages of COVID-19, everyone has suffered from COVID-19 for a long time. If this COVID-19-specific drug can effectively reduce the harm suffered by COVID-19 patients, that's really good news.